Discover Halozyme Therapeutics' impressive 2024 financials, featuring $1.015B revenue and 58% net income growth. Explore key metrics and investment insights.
Explore the latest 8-K filing from Halozyme Therapeutics, Inc. detailing significant events as of February 18, 2025. Stay informed on key updates for investors!
Explore Halozyme Therapeutics, Inc.'s 8-K filing from February 11, 2025, detailing crucial company updates, stock information, and significant events impacting shareholders.
Explore the latest 8-K filing by Halozyme Therapeutics, Inc., covering vital corporate changes on January 8, 2025. Stay informed on stock performance and investor relations.